BaoqiangCPU (Talk | contribs) |
|||
Line 30: | Line 30: | ||
<p class="body-title" style="padding-top:100px">Description</p> | <p class="body-title" style="padding-top:100px">Description</p> | ||
<div class="content" style="margin-top:60px"> | <div class="content" style="margin-top:60px"> | ||
− | <h4>Rheumatoid arthritis (RA) is a serious chronic, inflammatory and systemic autoimmune disease. | + | <h4><br>Rheumatoid arthritis (RA) is a serious chronic, inflammatory and systemic autoimmune disease. |
− | < | + | <br>It is of great essence to develop a kind of novel cell-targeted therapy for RA because there is no radical cure |
− | for RA for the time being. | + | for RA for the time being. |
− | < | + | <br>To solve the problems existing in the current treatment of RA, we design and build a brand new immunotherapy. |
FOXP3+ regulatory T cells(Tregs), which can suppress and regulate immune reactions, are modified utilizing | FOXP3+ regulatory T cells(Tregs), which can suppress and regulate immune reactions, are modified utilizing | ||
a lentiviral vector system to express a chimeric antigen receptor(CAR) targeting inflammatory cells associated | a lentiviral vector system to express a chimeric antigen receptor(CAR) targeting inflammatory cells associated | ||
− | with RA. | + | with RA. |
− | + | <br>Meanwhile, we insert the Syn-Notch receptor to activate the functional stability pathway of Tregs in the | |
inflammatory environment, which enables them to play their role of immunosuppression in lesions more | inflammatory environment, which enables them to play their role of immunosuppression in lesions more | ||
− | efficiently and more stably. | + | efficiently and more stably. |
− | < | + | <br>These two redirections of the two different but interrelated systems on Tregs ensure this novel therapy a |
promising anti-RA effect. </h4> | promising anti-RA effect. </h4> | ||
</div> | </div> |
Revision as of 10:49, 1 November 2017
Our HEAD-Treg
Description